To evaluate the efficacy, safety and tolerability of Hilterapia® (High Intensity Laser Therapy) in the chronic articular inflammatory processes in haemophilic adult patients

To evaluate the efficacy, safety and tolerability of Hilterapia® (High Intensity Laser Therapy) in the chronic articular inflammatory processes in haemophilic adult patients: an interventional pilot multicentre study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN02847428

Enrollment

Registered

2011-09-13

Start date

2011-05-15

Completion date

Unknown

Last updated

2017-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haemophilia Haematological Disorders Haemophilia

Interventions

Therapy with the equipment ASA-SH1 involves 9 applications (3 applications per week x 3 weeks) of Hilterapia® with the following operating parameters: 1. Fluence: 360 to 760 mJ/cm2 2. Frequency: 10 -

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adult subjects with haemophilia A of any severity with or not suppressant 2. Age more than or equal to 18 years 3. Subjects who have been previously diagnosed with a chronic articular inflammatory process or hematoma 4. Subjects who have signed an informed written consent

Exclusion criteria

Exclusion criteria: Subjects with under way bleeding

Design outcomes

Primary

Measure	Time frame
1. Pain will be measured using the Visual Analogue Scale (VAS) score (0 = no pain, 10 = unbearable pain) at baseline (T1), T4, T7 and T10 visits 2. Nieschl?s Score and the articular state will be measured using Hemophilia Joint Health Score 2.0	—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026